OBJECTIVE: To determine the most critical symptoms in a national myotonic dystrophy type 1 (DM1) population and to identify the modifying factors that have the greatest effect on the severity of these symptoms. METHODS: We performed a cross-sectional study of 278 adult patients with DM1 from the national registry of patients with DM1 between April and August 2010. We assessed the prevalence and relative significance of 221 critical DM1 symptoms and 14 disease themes. These symptoms and themes were chosen for evaluation based on prior interviews with patients with DM1. Responses were categorized by age, CTG repeat length, gender, and duration of symptoms. RESULTS: Participants with DM1 provided symptom rating survey responses to address the relative frequency and importance of each DM1 symptom. The symptomatic themes with the highest prevalence in DM1 were problems with hands or arms (93.5%), fatigue (90.8%), myotonia (90.3%), and impaired sleep or daytime sleepiness (87.9%). Participants identified fatigue and limitations in mobility as the symptomatic themes that have the greatest effect on their lives. We found an association between age and the average prevalence of all themes (p < 0.01) and between CTG repeat length and the average effect of all symptomatic themes on participant lives (p < 0.01). CONCLUSIONS: There are a wide range of symptoms that significantly affect the lives of patients with DM1. These symptoms, some previously underrecognized, have varying levels of importance in the DM1 population and are nonlinearly dependent on patient age and CTG repeat length.
OBJECTIVE: To determine the most critical symptoms in a national myotonic dystrophy type 1 (DM1) population and to identify the modifying factors that have the greatest effect on the severity of these symptoms. METHODS: We performed a cross-sectional study of 278 adult patients with DM1 from the national registry of patients with DM1 between April and August 2010. We assessed the prevalence and relative significance of 221 critical DM1 symptoms and 14 disease themes. These symptoms and themes were chosen for evaluation based on prior interviews with patients with DM1. Responses were categorized by age, CTG repeat length, gender, and duration of symptoms. RESULTS:Participants with DM1 provided symptom rating survey responses to address the relative frequency and importance of each DM1 symptom. The symptomatic themes with the highest prevalence in DM1 were problems with hands or arms (93.5%), fatigue (90.8%), myotonia (90.3%), and impaired sleep or daytime sleepiness (87.9%). Participants identified fatigue and limitations in mobility as the symptomatic themes that have the greatest effect on their lives. We found an association between age and the average prevalence of all themes (p < 0.01) and between CTG repeat length and the average effect of all symptomatic themes on participant lives (p < 0.01). CONCLUSIONS: There are a wide range of symptoms that significantly affect the lives of patients with DM1. These symptoms, some previously underrecognized, have varying levels of importance in the DM1 population and are nonlinearly dependent on patient age and CTG repeat length.
Authors: M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy Journal: Science Date: 1992-03-06 Impact factor: 47.728
Authors: Y H Fu; A Pizzuti; R G Fenwick; J King; S Rajnarayan; P W Dunne; J Dubel; G A Nasser; T Ashizawa; P de Jong Journal: Science Date: 1992-03-06 Impact factor: 47.728
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-02-21 Impact factor: 41.582
Authors: Catherine Acquadro; Rick Berzon; Dominique Dubois; Nancy Kline Leidy; Patrick Marquis; Dennis Revicki; Margaret Rothman Journal: Value Health Date: 2003 Sep-Oct Impact factor: 5.725
Authors: M Gennarelli; G Novelli; F Andreasi Bassi; L Martorell; M Cornet; E Menegazzo; M L Mostacciuolo; J M Martinez; C Angelini; A Pizzuti; M Baiget; B Dallapiccola Journal: Am J Med Genet Date: 1996-11-11
Authors: James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley Journal: J Neurol Date: 2013-06-27 Impact factor: 4.849
Authors: Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley Journal: Muscle Nerve Date: 2015-12-29 Impact factor: 3.217
Authors: Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley Journal: J Neurol Date: 2016-10-12 Impact factor: 4.849
Authors: Nicholas E Johnson; Anne-Berit Ekstrom; Craig Campbell; Man Hung; Heather R Adams; Wei Chen; Elizabeth Luebbe; James Hilbert; Richard T Moxley; Chad R Heatwole Journal: Dev Med Child Neurol Date: 2015-10-28 Impact factor: 5.449
Authors: Auinash Kalsotra; Ravi K Singh; Priyatansh Gurha; Amanda J Ward; Chad J Creighton; Thomas A Cooper Journal: Cell Rep Date: 2014-01-09 Impact factor: 9.423
Authors: Joseph Cheung; Chad Ruoff; Hyatt Moore; Katharine A Hagerman; Jennifer Perez; Sarada Sakamuri; Simon C Warby; Emmanuel Mignot; John Day; Jacinda Sampson Journal: J Clin Sleep Med Date: 2018-02-15 Impact factor: 4.062
Authors: Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann Journal: Neuromuscul Disord Date: 2014-06-27 Impact factor: 4.296